Imagine a tiny ring that acts like a slow-release battery for pain medication. Instead of using addictive strong drugs that make patients groggy, this ring sits right where the surgery happened and leaks a numbing agent slowly for three days. It helps people get out of bed and start moving much sooner after back surgery.
Patients undergoing spine surgery suffer from debilitating pain that is currently treated with addictive opioids. These opioids cause toxic side effects that delay recovery and increase the length of expensive hospital stays.
A drug delivery device called Bupi-Ring that releases bupivacaine at the surgical site for over 72 hours.
If you are a surgical implant manufacturer dealing with the limitations of standard pain management — this project developed Bupi-Ring that delivers bupivacaine for more than 72 hours. This allows for a non-opioid solution integrated directly into the surgical site.
If you are a private hospital dealing with extended hospital stays due to opioid side effects — this project developed a drug delivery system that promotes early mobilisation. This can shorten hospital stays and reduce the cost of post-operative care.
If you are a pharma company dealing with the short half-life of bupivacaine — this project developed a delivery technology that extends the effect of the drug. This transforms a short-term blocker into a 72-hour recovery tool.
Based on available project data, the specific unit price or cost of the device is not disclosed; however, the project aims to save overall healthcare costs by shortening hospital stays.
The project is currently in a Phase Ib clinical trial with small cohorts. Industrial scale production will likely follow the planned pivotal trial of approximately 200 patients.
Based on available project data, the technology is being developed by SentryX BV, but specific licensing terms or patent numbers are not provided in the summary.
The current project runs until 2026-03-31 to demonstrate safety. A pivotal trial of approximately 200 patients is required for approval in Europe and the United States.
The Bupi-Ring is designed to deliver medication without changing the existing surgical workflow during spine fixation surgery.
The project is led by a single SME, SentryX BV from the Netherlands, representing a 100% industry ratio. This lean structure suggests a highly focused commercial drive, though it relies on external strategic partners for financial and instrumental market access support rather than a diverse academic consortium.
Contact SentryX BV in the Netherlands regarding Bupi-Ring clinical data
Contact us to find similar non-opioid drug delivery innovations.
